½ÃÀ庸°í¼­
»óǰÄÚµå
1608113

¼¼°èÀÇ ÈíÀÔ °¡´É ¾àÁ¦ ½ÃÀå : Á¦Ç°º°, ¿ëµµº° ¿¹Ãø(2025-2030³â)

Inhalable Drugs Market by Product (Aerosol, Dry Powder Formulation, Spray), Application (Non-Respiratory Diseases, Respiratory Diseases) - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 188 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

ÈíÀÔ °¡´É ¾àÁ¦ ½ÃÀåÀº 2023³â¿¡ 350¾ï 1,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³â¿¡´Â 376¾ï ´Þ·¯¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 6.05%·Î ¼ºÀåÇÏ¿©, 2030³â¿¡´Â 528¾ï 4,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ÈíÀÔ °¡´É ¾àÁ¦Àº õ½ÄÀ̳ª COPD¿Í °°Àº È£Èí±â Áúȯ¿¡¼­ ½Å¼ÓÇÑ Èí¼ö¿Í Ç¥Àû ÀÛ¿ëÀÇ ÀáÀçÀûÀÎ ÀÌÁ¡À» Á¦°øÇϴ ȣÈí±â ½Ã½ºÅÛÀ» ÅëÇÑ Àü´ÞÀ» À§ÇØ ¼³°èµÈ Á¦Á¦ÀÔ´Ï´Ù. Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ´Â °ÍÀº ¸¸¼º È£Èí±â ÁúȯÀÇ °ü¸®¿¡ À־ Áß¿äÇÑ ¿ªÇÒ°ú ÀÌ·¯ÇÑ ÁúȯÀÇ ¼¼°èÀÇ À¯º´·ü Áõ°¡¿¡ ±âÀÎÇϰí ÀÖ½À´Ï´Ù. ½ÉÁö¾î »¡ ÀÔ¿¡ ÀÇÇÑ ºñħ½ÀÀû Åõ¿©°¡ °¡´ÉÇÑ ¹é½Å µîÀÇ ¾à¹° Åõ¿©¿¡ À̸£´Â ±× ¿ëµµ¿¡ ÀÇÇØ °­È­µÇ°í ÀÖ½À´Ï´Ù. ½ÃÀå ¼ºÀåÀº È£Èí±â Áúȯ·ü Áõ°¡, ¾à¹° Àü´Þ ½Ã½ºÅÛÀÇ ±â¼ú Áøº¸, È¿À²ÀûÀ̰í ȯÀÚ Ä£È­Àû ÀÎ Ä¡·á ¿É¼Ç ¼ö¿ä¿Í °°Àº ¿äÀο¡ Å©°Ô ¿µÇâÀ»¹Þ½À´Ï´Ù. ¼¼ºÐÈ­ ±âȸ´Â ½ÅÈï±¹ ½ÃÀåÀÇ È®´ë, ½º¸¶Æ® ÈíÀÔ±â¿Í °°Àº ÀûÀÀ ±â¼ú, ¸ÂÃãÇü ÀÇ·á ¹× »ý¹° Á¦Á¦ÀÇ ±â¼ú Çõ½Å¿¡ ÀÇÇÑ COPD¿Í õ½Ä ºÐ¾ßÀÇ ¼ºÀå¿¡ ÀÖ½À´Ï´Ù. »ç¿ëÇϱâ À§ÇØ ÀÌÇØ°ü°èÀÚ´Â »ý»ê´É·Â È®´ë, ±ÔÁ¦ ´ëÀÀ, Á¦Ç° °³¹ß ¹× À¯ÅëÀ» À§ÇÑ Àü·«Àû ÆÄÆ®³Ê½Ê¿¡ ÁÖ·ÂÇØ¾ß ÇÕ´Ï´Ù. ºÎÀÛ¿ëÀÇ °¡´É¼º, °³¹ß ºñ¿ëÀÇ ³ôÀÌ µîÀÇ ÇѰ迡 Á÷¸éÇϰí ÀÖ½À´Ï´Ù. ´Â Åõ¿© Á¤¹Ðµµ¸¦ ³ôÀ̱â À§ÇÑ ÈíÀԱ⠼³°è °³¼±, »ýüÀÌ¿ë·üÀ» Çâ»ó½ÃŲ ¾àÁ¦ÀÇ Ã³¹æ, ȯÀÚÀÇ ÄÄÇöóÀ̾𽺸¦ °¨½Ã, °³¼±Çϱâ À§ÇÑ µðÁöÅÐ Çコ ±â¼úÀÇ ÅëÇÕ µîÀÌ ÀÖ½À´Ï´Ù.»ç¿ëÀÚ °æÇèÀ» ÀÌÇØÇÏ°í ±âÁ¸ ¼³°è»óÀÇ ´ÜÁ¡À» ÇØ°áÇÔÀ¸·Î½á ÃæÁ·µÇÁö ¾ÊÀº ½ÃÀå ¿ä±¸¿¡ ´ëÇÑ ½Ç¿ëÀûÀÎ ÀλçÀÌÆ®À» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù. ±â¼ú°ú Çõ½ÅÀÌ ÁÖ¿ä ÃËÁø¿äÀÎÀ¸·Î ÀÚ¸®¸Å±èµÇ´Â ¹Ý¸é, ¾ö°ÝÇÑ ±ÔÁ¦¿Í ½ÃÀå ħÅõÀÇ °úÁ¦¸¦ ±Øº¹ÇÏ´Â °ÍÀÌ ¹Ì·¡ÀÇ ¼º°øÀ» À§ÇØ ¿©ÀüÈ÷ Áß¿äÇÕ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ(2023) 350¾ï 1,000¸¸ ´Þ·¯
ÃßÁ¤³â(2024) 376¾ï ´Þ·¯
¿¹Ãø³â(2030) 528¾ï 4,000¸¸ ´Þ·¯
º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)(%) 6.05%

½ÃÀå ¿ªÇÐ : ºü¸£°Ô ÁøÈ­ÇÏ´Â ÈíÀÔ °¡´É ¾àÁ¦ ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

ÈíÀÔ °¡´É ¾àÁ¦ ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ ÀÛ¿ë¿¡ ÀÇÇØ º¯¸ð¸¦ ÀÌ·ç°í ÀÖ½À´Ï´Ù. »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ ¾ò´Â µ¥ µµ¿òÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ °æ°¨ÇÒ ¼ö ÀÖÀ½°ú µ¿½Ã¿¡ ¼ÒºñÀÚ Çൿ°ú ±×°Í Á¦Á¶ ºñ¿ë°ú ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ»º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ¸¸¼º Æó»ö¼º Æó ÁúȯÀ̳ª õ½Ä µîÀÇ È£Èí±â ÁúȯÀÇ ÀÌȯÀ²ÀÇ »ó½Â
    • ÇコÄɾî ÀÎÇÁ¶ó Áõ°¡¿Í ȯÀÚÀÇ ÀÇ½Ä Áõ°¡
    • ÆÄŲ½¼º´ µî ºñÈ£Èí±â ÁúȯÀÇ ±ÞÁõ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ÈíÀÔ °¡´É ¾àÁ¦ÀÇ ½ÂÀο¡ °üÇÑ ¾ö°ÝÇÑ ±ÔÁ¦
  • ½ÃÀå ±âȸ
    • Åõ¿©Çϱ⠽¬¿î ÈíÀÔ °¡´É ¾àÁ¦ÀÇ °³¹ß ±ÞÁõ
    • ¾à¹° Àü´ÞÀ» °³¼±Çϱâ À§ÇØ, ÇöÀçÀÇ ºñÈíÀÔÇü ºÐÀÚ¸¦ ÈíÀÔÇü ºÐÀÚ·Î °³·®ÇÏ´Â ¿òÁ÷ÀÓÀÌ È°¼ºÈ­
  • ½ÃÀåÀÇ °úÁ¦
    • ±ÔÁ¦µÇÁö ¾ÊÀº ´ëü¿ä¹ýÀÇ À̿밡´É¼º

Porter's Five Forces : ÈíÀÔ °¡´É ¾àÁ¦ ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Porter's Five Forces Framework´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Porter's Five Forces Framework´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ ޱ¸ÇÏ´Â ¸íÈ®ÇÑ ±â¼úÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÀλçÀÌÆ®À» ÅëÇØ ±â¾÷Àº ÀÚ»çÀÇ °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ °úÁ¦¸¦ ÇÇÇÒ ¼ö ÀÖÀ¸¸ç, º¸´Ù °­ÀÎÇÑ ½ÃÀå¿¡¼­ÀÇ Æ÷Áö¼Å´×À» º¸ÀåÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ÈíÀÔ °¡´É ¾àÁ¦ ½ÃÀå¿¡¼­ ¿ÜºÎ ¿µÇâÀ» ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ÈíÀÔ °¡´É ¾àÁ¦ ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ»ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀÎ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¾ÕÀ¸·Î ¿¹»óµÇ´Â Àû±ØÀûÀÎ ÀÇ»ç °áÁ¤À» ÇÒ Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® ÈíÀÔ °¡´É ¾àÁ¦ ½ÃÀå °æÀï ±¸µµ ÆÄ¾Ç

ÈíÀÔ °¡´É ¾àÁ¦ ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü µî ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀï Æ÷Áö¼Å´×À» ¹àÈú ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ½ÃÀå ÁýÁß, ´ÜÆíÈ­, ÅëÇÕ µ¿ÇâÀ» ¹àÇô³»°í º¥´õµéÀº °æÀïÀÌ Ä¡¿­ÇØÁö´Â °¡¿îµ¥ ÀÚ»çÀÇ ÁöÀ§¸¦ ³ôÀÌ´Â Àü·«Àû ÀÇ»ç °áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ Áö½ÄÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º ÈíÀÔ °¡´É ¾àÁ¦ ½ÃÀå¿¡¼­ °ø±Þ¾÷üÀÇ ¼º´É Æò°¡

FPNV Positioning Matrix´Â ÈíÀÔ °¡´É ¾àÁ¦ ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ Çà·ÄÀ» ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº °ø±Þ¾÷üÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±âÁØÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ¸Â´Â ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. ³× °¡Áö »çºÐ¸éÀ» ÅëÇØ °ø±Þ¾÷ü¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê ¹× ¼Ö·ç¼ÇÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× ±ÇÀå ÈíÀÔ °¡´É ¾àÁ¦ ½ÃÀå¿¡¼­ ¼º°ø¿¡ ´ëÇÑ ±æÀ» ±×¸³´Ï´Ù.

ÈíÀÔ °¡´É ¾àÁ¦ ½ÃÀåÀÇ Àü·« ºÐ¼®Àº ½ÃÀå¿¡¼­ÀÇ ÇÁ·¹Á𽺠°­È­¸¦ ¸ñÇ¥·Î ÇÏ´Â ±â¾÷¿¡ ÇʼöÀûÀÔ´Ï´Ù. ÀÌ Á¢±Ù¹ýÀ» ÅëÇØ °æÀï ±¸µµ¿¡¼­ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ üÁ¦¸¦ ±¸ÃàÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀåÀÇ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ : ½ÅÈï ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡ÇÏ¸ç ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù¾çÈ­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú Áøº¸ µîÀ» °ËÁõÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÃÖ÷´Ü ±â¼ú, R&D Ȱµ¿, Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¾ò°í ÀÇ»ç°áÁ¤À» ÇÒ ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡ ´ë´äÇϰí ÀÖ½À´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹® ¹× Áö¿ªÀº ¾îµðÀԴϱî?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ, ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • ¸¸¼º Æó»ö¼º Æó ÁúȯÀ̳ª õ½Ä µîÀÇ È£Èí±â ÁúȯÀÇ ¹ß»ý·üÀÇ »ó½Â
      • ÇコÄɾî ÀÎÇÁ¶óÀÇ °­È­¿Í ȯÀÚÀÇ ÀÇ½Ä Çâ»ó
      • ÆÄŲ½¼º´ µî ºñÈ£Èí±â ÁúȯÀÇ ±ÞÁõ
    • ¾ïÁ¦¿äÀÎ
      • ÈíÀÔ °¡´É ¾àÁ¦ÀÇ ½ÂÀο¡ °üÇÑ ¾ö°ÝÇÑ ±ÔÁ¦
    • ±âȸ
      • °ü¸®¸¦ ¿ëÀÌÇÏ°Ô ÇÏ´Â ÈíÀÔ °¡´É ¾àÁ¦ÀÇ °³¹ßÀÌ ±ÞÁõ
      • ¾à¹°Àü´Þ¸¦ °³¼±Çϱâ À§Çؼ­, ÇöÀçÀÇ ºñÈíÀÔ ºÐÀÚ¸¦ ÈíÀÔ ºÐÀÚ¿¡ Àç¹èÇÕÇÏ´Â ¿òÁ÷ÀÓÀÌ È°¹ßÇØÁö°í ÀÖ´Ù
    • °úÁ¦
      • ±ÔÁ¦µÇÁö ¾ÊÀº ´ëü¿ä¹ýÀÇ À̿밡´É¼º
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡Àû
    • °æÁ¦
    • »ç±³
    • ±â¼úÀû
    • ¹ý·ü»ó
    • ȯ°æ

Á¦6Àå ÈíÀÔ °¡´É ¾àÁ¦ ½ÃÀå : Á¦Ç°º°

  • ¿¡¾î·ÎÁ¹
  • °ÇÁ¶ ºÐ¸» Á¦Çü
  • ½ºÇÁ·¹ÀÌ

Á¦7Àå ÈíÀÔ °¡´É ¾àÁ¦ ½ÃÀå : ¿ëµµº°

  • È£Èí±â°è ÀÌ¿ÜÀÇ Áúȯ
  • È£Èí±â Áúȯ

Á¦8Àå ¾Æ¸Þ¸®Ä«ÀÇ ÈíÀÔ °¡´É ¾àÁ¦ ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦9Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÈíÀÔ °¡´É ¾àÁ¦ ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦10Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ÈíÀÔ °¡´É ¾àÁ¦ ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦11Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®(2023³â)
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º(2023³â)
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸ñ·Ï

  • Aptargroup, Inc.
  • AstraZeneca PLC
  • Avalyn Pharma, Inc.
  • Boehringer Ingelheim International GmbH
  • Cipla Inc.
  • GEA Group Aktiengesellschaft
  • Merck & Co. Inc.
  • Novartis AG
  • Orion Corporation
  • Pfizer Inc.
  • PureIMS BV
  • Respira Therapeutics Inc.
  • Sanofi SA
  • Sunovion Pharmaceuticals Inc. by Sumitomo Dainippon Pharma Co. Ltd.
  • Teva Pharmaceutical Industries Ltd.
BJH 24.12.19

The Inhalable Drugs Market was valued at USD 35.01 billion in 2023, expected to reach USD 37.60 billion in 2024, and is projected to grow at a CAGR of 6.05%, to USD 52.84 billion by 2030.

Inhalable drugs are formulations designed for delivery through the respiratory system, offering potential advantages in rapid absorption and targeted action in respiratory conditions like asthma and COPD. The growing necessity for inhalable drugs stems from their critical role in managing chronic respiratory diseases and the increasing prevalence of such conditions globally. This necessity is bolstered by their applications, which span administering medication for systemic disease treatments, pain management, and even vaccines where inhalation offers non-invasive administration. End-users include hospitals, clinics, and home care settings, reflecting the broad adoption of these drugs. Market growth is heavily influenced by factors like rising respiratory disease rates, technological advancements in drug delivery systems, and demand for efficient, patient-friendly treatment options. Opportunities lie in expanding markets in developing regions, adaptive technologies like smart inhalers, and growth in COPD and asthma segments, driven by innovation in personalized medicine and biologics. To tap into these potentials, stakeholders should focus on expanding production capabilities, regulatory compliance, and strategic partnerships for product development and distribution. Despite the promising outlook, the market faces limitations such as regulatory challenges, potential side effects; and high development costs. Competition from oral medications and ongoing research in alternative therapies add to these challenges. Areas ripe for innovation include enhancing inhaler design for better dose accuracy, formulating drugs with improved bioavailability, and integration of digital health technologies to monitor and improve patient compliance. Understanding user experiences and addressing existing design drawbacks can provide actionable insights into unmet market needs. Overall, the inhalable drugs market shows dynamic growth potential, with technology and innovation positioned as key drivers while overcoming stringent regulations and market penetration challenges remain important for future success.

KEY MARKET STATISTICS
Base Year [2023] USD 35.01 billion
Estimated Year [2024] USD 37.60 billion
Forecast Year [2030] USD 52.84 billion
CAGR (%) 6.05%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Inhalable Drugs Market

The Inhalable Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidence of respiratory diseases such as chronic obstructive pulmonary diseases and asthma
    • Increasing healthcare infrastructure and rising awareness among patients
    • Surge in the number of non-respiratory diseases such as Parkinson's disease
  • Market Restraints
    • Strict regulations for the approval of inhalable drugs
  • Market Opportunities
    • Surge in development of inhalable drugs for ease of administration
    • Emerging reformulation of current non-inhaled molecules into inhaled molecules for improved drug delivery
  • Market Challenges
    • Availability of unregulated and alternate therapy

Porter's Five Forces: A Strategic Tool for Navigating the Inhalable Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Inhalable Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Inhalable Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Inhalable Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Inhalable Drugs Market

A detailed market share analysis in the Inhalable Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Inhalable Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Inhalable Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Inhalable Drugs Market

A strategic analysis of the Inhalable Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Inhalable Drugs Market, highlighting leading vendors and their innovative profiles. These include Aptargroup, Inc., AstraZeneca PLC, Avalyn Pharma, Inc., Boehringer Ingelheim International GmbH, Cipla Inc., GEA Group Aktiengesellschaft, Merck & Co., Inc., Novartis AG, Orion Corporation, Pfizer Inc., PureIMS B.V., Respira Therapeutics Inc., Sanofi S.A., Sunovion Pharmaceuticals Inc. by Sumitomo Dainippon Pharma Co., Ltd., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Inhalable Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Aerosol, Dry Powder Formulation, and Spray.
  • Based on Application, market is studied across Non-Respiratory Diseases and Respiratory Diseases.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidence of respiratory diseases such as chronic obstructive pulmonary diseases and asthma
      • 5.1.1.2. Increasing healthcare infrastructure and rising awareness among patients
      • 5.1.1.3. Surge in the number of non-respiratory diseases such as Parkinson's disease
    • 5.1.2. Restraints
      • 5.1.2.1. Strict regulations for the approval of inhalable drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Surge in development of inhalable drugs for ease of administration
      • 5.1.3.2. Emerging reformulation of current non-inhaled molecules into inhaled molecules for improved drug delivery
    • 5.1.4. Challenges
      • 5.1.4.1. Availability of unregulated and alternate therapy
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Inhalable Drugs Market, by Product

  • 6.1. Introduction
  • 6.2. Aerosol
  • 6.3. Dry Powder Formulation
  • 6.4. Spray

7. Inhalable Drugs Market, by Application

  • 7.1. Introduction
  • 7.2. Non-Respiratory Diseases
  • 7.3. Respiratory Diseases

8. Americas Inhalable Drugs Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Inhalable Drugs Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Inhalable Drugs Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Aptargroup, Inc.
  • 2. AstraZeneca PLC
  • 3. Avalyn Pharma, Inc.
  • 4. Boehringer Ingelheim International GmbH
  • 5. Cipla Inc.
  • 6. GEA Group Aktiengesellschaft
  • 7. Merck & Co., Inc.
  • 8. Novartis AG
  • 9. Orion Corporation
  • 10. Pfizer Inc.
  • 11. PureIMS B.V.
  • 12. Respira Therapeutics Inc.
  • 13. Sanofi S.A.
  • 14. Sunovion Pharmaceuticals Inc. by Sumitomo Dainippon Pharma Co., Ltd.
  • 15. Teva Pharmaceutical Industries Ltd.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦